Binding Activity Difference of Anti-CD20 scFv-Fc Fusion Protein Derived from Variable Domain Exchange

被引:0
|
作者
Geng, Shusheng [1 ,2 ]
Feng, Jiannan [2 ,3 ]
Li, Yan [2 ,3 ]
Sun, Yingxun [2 ]
Gu, Xin [2 ]
Huang, Ying [2 ]
Wang, Yugang [2 ]
Kang, Xianjiang [1 ]
Chang, Hong [2 ]
Shen, Beifen [2 ]
机构
[1] Hebei Univ, Coll Life Sci, Baoding, Hebei, Peoples R China
[2] Inst Basic Med Sci, Beijing 100850, Peoples R China
[3] Henan Univ, Sch Med, Cellular & Mol Immunol Lab, Kaifeng, Henan, Peoples R China
基金
中国国家自然科学基金;
关键词
binding activity; scFv-Fc; variable domain exchange; molecular modeling;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two novel engineered antibody fragments binding to antigen CD20 were generated by fusing a murine IgM-type anti-CD20 single-chain Fv fragment (scFv) to the human IgG1 CH2 (i.e., C(gamma)2) and CH3 (i.e., C(gamma)3) domains with the human IgG1 hinge (i.e. H-gamma). Given the relationship between structure and function of protein, the 3-D structures of the two engineered antibody fragments were modeled using computer-aided homology modeling method. Furthermore, the relationship between 3-D conformation and their binding activity was evaluated theoretically. Due to the change of active pocket formed by CDRs, the HL23 (V-H-Linker-V-L-H-gamma-C(gamma)2- C(gamma)3) remained its activity because of its preserved conformation, while the binding activity of the LH23 (V-L-Linker-V-H-H-gamma-C(gamma)2-C(gamma)3) was impaired severely. Experimental studies by flow cytometry and fluorescence microscopy showed that HL23 possessed significantly superior binding activity to CD20-expressing target cells than LH23. That is to say, the order of variable regions could influence the binding activity of the fusion protein to CD20(+) cell lines, which was in accordance with the theoretical results. The study highlights the potential relationship between the antibody binding activity and their 3-D conformation, which appears to be worthwhile in providing direction for future antibody design of recombinant antibody.
引用
收藏
页码:439 / 443
页数:5
相关论文
共 50 条
  • [1] Binding Activity Difference of Anti-CD20 scFv-Fc Fusion Protein Derived from Variable Domain Exchange
    Shusheng Geng1
    2Institute of Basic Medical Sciences
    3Lab of Cellular and Molecular Immunology
    Cellular&MolecularImmunology, 2006, (06) : 439 - 443
  • [2] Enhancing the Secretion of a Glyco-Engineered Anti-CD20 scFv-Fc Antibody in Hairy Root Cultures
    Lonoce, Chiara
    Marusic, Carla
    Morrocchi, Elena
    Salzano, Anna Maria
    Scaloni, Andrea
    Novelli, Flavia
    Pioli, Claudio
    Feeney, Mistianne
    Frigerio, Lorenzo
    Donini, Marcello
    BIOTECHNOLOGY JOURNAL, 2019, 14 (03)
  • [3] Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange
    Wu, AM
    Tan, GJ
    Sherman, MA
    Clarke, P
    Olafsen, T
    Forman, SJ
    Raubitschek, AA
    PROTEIN ENGINEERING, 2001, 14 (12): : 1025 - 1033
  • [4] Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies
    Smolewski, Piotr
    Robak, Pawel
    Cebula-Obrzut, Barbara
    Misiewicz, Malgorzata
    Medra, Aleksandra
    Majchrzak, Agata
    Witkowska, Magdalena
    Stromatt, Scott
    Robak, Tadeusz
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (15) : 2677 - 2684
  • [5] Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies
    Smolewski, Piotr
    Pawel, Robak
    Cebula-Obrzut, Barbara
    Misiewicz, Malgorzata
    Jeske, Aleksandra
    Majchrzak, Agata
    Stromatt, Scott
    Robak, Tadeusz
    BLOOD, 2011, 118 (21) : 722 - 723
  • [6] Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin
    FANG Hong 1
    2 Institute of Hematology & Hospital of Blood Diseases
    3 Cancer Institute & Hospital
    Science China(Life Sciences), 2011, (03) : 255 - 262
  • [7] Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin
    Fang Hong
    Miao QingFang
    Zhang ShengHua
    Cheng Xin
    Xiong DongSheng
    Zhen YongSu
    SCIENCE CHINA-LIFE SCIENCES, 2011, 54 (03) : 255 - 262
  • [8] Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin
    FANG Hong MIAO QingFang ZHANG ShengHua CHENG Xin XIONG DongSheng ZHEN YongSu Institute of Medicinal BiotechnologyChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing China Institute of Hematology Hospital of Blood DiseasesChinese Academy of Medical Sciences and Peking Union Medical CollegeTianjin China Cancer Institute HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing China
    Science China(Life Sciences), 2011, 54 (03) : 255 - 262
  • [9] Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin
    Hong Fang
    QingFang Miao
    ShengHua Zhang
    Xin Cheng
    DongSheng Xiong
    YongSu Zhen
    Science China Life Sciences, 2011, 54 : 255 - 262
  • [10] Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library
    Shams, Nasir
    Nikkhoi, Shahryar Khoshtinat
    Gu, Zhanjun
    Rahbarizadeh, Fatemeh
    MEDICAL ONCOLOGY, 2022, 39 (11)